Rigel Pharmaceuticals(RIGL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 3.11 | EPS (ttm) | 16.32 | Insider Own | 3.32% | Shs Outstand | 18.6M | Perf Week | 3.81% |
| Market Cap | 0.95B | Forward P/E | 11.08 | EPS next Y | 33.56% | Insider Trans | -0.8% | Shs Float | 18.1M | Perf Month | 3.78% |
| Enterprise Value | 0.89B | PEG | - | EPS next Q | 0.92 | Inst Own | 91.89% | Short Float | 15.13% | Perf Quarter | 33.32% |
| Income | 0.32B | P/S | 3.42 | EPS this Y | -82.39% | Inst Trans | -7.3% | Short Ratio | 10.55 | Perf Half Y | 73.65% |
| Sales | 0.28B | P/B | 2.22 | EPS next 5Y | - | ROA | 88.46% | Short Interest | 2.73M | Perf YTD | 18.47% |
| Book/sh | 22.81 | P/C | 9.94 | EPS past 3/5Y | - | ROE | 126.9% | 52W High | -2.87% ($52.24) | Perf Year | 70.9% |
| Cash/sh | 5.1 | P/FCF | 11.94 | Sales past 3/5Y | 34.76% 22.06% | ROIC | 75.66% | 52W Low | 103.37% ($24.95) | Perf 3Y | 594.88% |
| Dividend Est. | - | EV/EBITDA | 9.95 | EPS Y/Y TTM | 221.64% | Gross Margin | 91.39% | Volatility(W/M) | 2.68% 3.67% | Perf 5Y | 53.76% |
| Dividend TTM | - | EV/Sales | 3.22 | Sales Y/Y TTM | 3.31% | Oper. Margin | 31.45% | ATR (14) | 1.66 | Perf 10Y | 95.91% |
| Dividend Ex-Date | - | Quick Ratio | 1.79 | EPS Q/Q | -73.08% | Profit Margin | 116.3% | RSI (14) | 62.9 | Recom | 1.8 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.94 | Sales Q/Q | -22.6% | SMA20 | 5.52% ($48.09) | Beta | 1.28 | Target Price | $63 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/8/4 | SMA50 | 6.86% ($47.48) | Rel Volume | 0.87 | Prev Close | $50.55 |
| Employees | 174 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 903.42% 42.39% | SMA200 | 37.07% ($37.02) | Avg Volume(3M) | 0.26M | Price | $50.74 |
| IPO | 2000/11/29 | Option/Short | Yes/Yes | Trades | 3751 | Volume | 226,373 | Change | 0.38% |
💊 Rigel Pharmaceuticals (RIGL) is a U.S. commercial-stage biotech company that develops and markets small-molecule drugs targeting rare diseases such as immune and hematologic disorders and cancer. The company has secured a position in the spleen tyrosine kinase (Syk) inhibitor class and has established itself as a revenue-generating company with marketed products in chronic immune thrombocytopenia and acute myeloid leukemia.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded about as much as usual. That is 87% of its average volume.
RIGL makes money exceptionally well
Of every $100 in sales, $31.45 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -82.4% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $1,108. Peers typically go for $1,500. Compared with its own 2-year average, it is 44% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +53.8%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 91.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #163 of 594 in the industry
Based on market cap of $948M.
KURA#161 Kura Oncology Inc $954M PER - 
ALMS#162 Alumis Inc $952M PER - RIGL#163 Rigel Pharmaceuticals $948M PER 3.1 
ODTX#164 Odyssey Therapeutics Inc $939M PER - 
MGTX#165 MeiraGTx Holdings plc $936M PER 13.8 
FAQ
What kind of company is RIGL?
RIGL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RIGL?
The market cap of RIGL is approximately $948M, ranking 2,629 within its sector.
What is the P/E ratio of RIGL?
RIGL has a P/E ratio of approximately 3.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for RIGL?
RIGL has recorded a 52-week high of $52.24 and a low of $24.95.
